Investor Presentation - First Six Months of 2021
74
Thrombin Peak (nM)
Investor presentation First six months of 2021
Next-generation FVIII mimentic, Mim8, is a bispecific antibody
for s.c. prophylaxis treatment in people with haemophilia A
400
Thrombin generation assay
HA plasma + FVIII
150
Thromboelastography
HA
Characteristics
• Strong activity at site of bleeding
Minimised target binding in circulation
Delivered in an innovative device
300
200
100
Mim8
emicizumab¹
HA
Clot time, R-time (min)
100
50
Mim8
emicizumab¹
Normal control
0
0
0.1
1
10
Antibody (nM)
100
1000
0.01
0.1
1
Antibody (nM)
10
| | |||||||
100
1000
Mim8 potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo
Phase 1/2 trial
• Initiated in January 2020 and expect results in
2021
Phase 1 is a single ascending dose part with
40 treated people
Phase 2 is a multiple ascending dose part with
32 treated people
• Trial investigates safety, tolerability, PK/PD of
single sc injections
ه
Mim8 effectively stops severe bleeds in mouse models
1 Sequence-identical-analogue (SIA) of the FVIII-mimicking bispecific antibody emicizumab; PK: pharmacokinetics; PD: pharmacodynamics; S.c.: subcutaneous
Novo Nordisk®View entire presentation